GL261 Syngeneic Model Overview
The GL261 syngeneic model is a murine glioblastoma multiforme (GBM) system derived from C57BL/6 mice and is one of the most widely used preclinical brain tumor models in immuno-oncology research. It represents a high-grade glioma characterized by aggressive growth, vascular proliferation, and an immunosuppressive tumor microenvironment. The GL261 model has been instrumental in evaluating immunotherapies, radiotherapy, and combination treatment strategies targeting the central nervous system.
When implanted intracranially or subcutaneously, GL261 cells form highly vascularized tumors with histopathological features closely resembling human glioblastoma, including pseudopalisading necrosis, microvascular proliferation, and invasive growth patterns. The model’s immunocompetent host background and reproducible tumor kinetics make it ideal for assessing immune checkpoint blockade, oncolytic virotherapy, T-cell therapies, and drug delivery systems that cross the blood–brain barrier.
Request a Custom Quote for GL261 Syngeneic ModelBiological and Molecular Characteristics
The GL261 cell line was originally induced in C57BL/6 mice using the chemical carcinogen methylcholanthrene and has since been maintained as a stable glioma cell line with mixed astrocytic and oligodendroglial features. These cells exhibit rapid proliferation, anchorage-independent growth, and the ability to form both intracranial and subcutaneous tumors. GL261 expresses wild-type p53 and elevated levels of Ras, contributing to oncogenic signaling through MAPK and PI3K pathways.
Molecular characterization of GL261 tumors reveals upregulation of immunosuppressive cytokines including TGF-beta and IL-10, as well as immune checkpoint molecules such as PD-L1. Despite their immunosuppressive phenotype, GL261 tumors are moderately immunogenic and can respond to immune activation under therapeutic conditions. This balance between immune evasion and partial responsiveness has made the GL261 model a cornerstone for studying the mechanisms of immune modulation in glioblastoma.
| Parameter | Description |
|---|---|
| Host strain | C57BL/6 (female, 6–8 weeks) |
| Tumor origin | Chemically induced glioblastoma (mouse) |
| Histological type | High-grade astrocytoma / glioblastoma multiforme |
| Inoculation route | Intracranial or subcutaneous |
| Tumor take rate | >90% |
| Doubling time | Approximately 3–4 days in vivo |
| Metastatic potential | Local invasion only; no systemic spread |
| Immunophenotype | Immunosuppressive; T-cell exclusion and macrophage dominance |
| Common applications | Immunotherapy, radiation, oncolytic virus therapy, CNS drug delivery |
In Vivo Model Development and Tumorigenicity
GL261 tumors can be established by either intracranial or subcutaneous implantation into immunocompetent C57BL/6 mice. The intracranial model is most commonly used, as it replicates the invasive growth, vascular proliferation, and immune suppression characteristic of human glioblastoma. Following stereotactic injection, tumors develop within 7–10 days and cause neurological symptoms by approximately day 18–25, depending on cell dose and site of implantation.
The subcutaneous model provides a convenient platform for monitoring tumor growth and response to therapy in real time. Both implantation routes yield reproducible tumor establishment and predictable progression, making GL261 highly suitable for studies of immune checkpoint inhibition, cytokine therapy, radiation–immunotherapy synergy, and drug delivery strategies designed to penetrate the blood–brain barrier.
Request a Custom Quote for GL261 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histopathological analysis of GL261 tumors shows pleomorphic, densely packed glial cells with high nuclear atypia, mitotic activity, and pseudopalisading necrosis, closely mirroring human glioblastoma. The tumor architecture is highly vascularized, with areas of hemorrhage and reactive gliosis at the tumor margins. In the intracranial model, infiltrative growth into adjacent brain parenchyma is commonly observed, consistent with aggressive glioma behavior.
Immunohistochemical staining demonstrates strong positivity for glial fibrillary acidic protein (GFAP), confirming glial origin. Ki-67 staining indicates high proliferative activity, while CD31 highlights extensive neovascularization. Immune profiling reveals infiltration by macrophages and microglia (F4/80 and Iba1 positive) and limited T-cell presence (CD3 and CD8 positive) within the tumor core, reflecting an immune-cold microenvironment. PD-L1 expression is moderate and inducible following interferon stimulation or treatment with checkpoint inhibitors. These features collectively establish GL261 as a histologically and immunologically relevant model for glioblastoma research.
Preclinical Applications and Drug Response
The GL261 syngeneic model is one of the most extensively used systems for evaluating therapeutic strategies in glioblastoma. It has demonstrated responsiveness to immune checkpoint inhibitors targeting PD-1 and CTLA-4 when combined with radiotherapy, cytokine therapy, or oncolytic virotherapy. The model’s partial immunogenicity enables the study of T-cell activation, immune memory, and resistance mechanisms in a physiologically relevant CNS environment.
GL261 is also widely used for preclinical testing of nanoparticle-based and liposomal drug delivery systems, particularly those designed to cross the blood–brain barrier. Radiation combined with PD-1 blockade has shown synergistic effects in this model, leading to prolonged survival and enhanced T-cell infiltration. Because of its reproducibility, immunocompetent context, and translational fidelity, GL261 remains the gold-standard syngeneic glioma model for immuno-oncology and neuro-oncology research.
Request This Model
To request the GL261 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for GL261 Syngeneic Model